dr. hamilton on the optimal duration of trastuzumab in her2 breast cancer
Published 5 years ago • 1.9K plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
1:13
dr. hamilton on the efficacy of trastuzumab deruxtecan in her2-low breast cancer
-
1:43
dr hamilton on implications of destiny-breast06 on the her2-low breast cancer paradigm
-
1:07
dr. hamilton on the destiny-breast01 trial in her2 breast cancer
-
0:43
dr. hamilton on fda approval of adjuvant pertuzumab regimen in her2 early breast cancer
-
0:56
dr. hamilton on recent advances in her2 breast cancer
-
1:18
dr. hamilton discusses the katherine trial in her2 breast cancer
-
1:16
the optimal duration of pertuzumab treatment for patients with her2 breast cancer
-
7:48
hologic ceo steve macmillan on breast cancer detection, future of ai-powered diagnostics
-
1:01
dr. hamilton discusses challenges with approved treatments for her2-positive breast cancer
-
1:13
dr. hamilton on overcoming resistance to her2-targeted therapy in breast cancer
-
1:10
dr. hamilton on the fda approval of tucatinib in her2 breast cancer
-
1:32
dr hamilton on the safety profile of adcs in her2-low and -ultralow breast cancer
-
1:01
dr. hamilton on research needed in her2-positive breast cancer
-
1:43
dr. hamilton on ont-380/t-dm1 in her2 breast cancer
-
1:05
dr. hamilton on the evolution of treatment in her2 breast cancer
-
1:53
dr. hamilton on adjuvant therapy for her2 breast cancer
-
1:07
dr. hamilton on the results of the nextmonarch trial in patients with hr /her2- breast cancer
-
1:29
dr. hamilton on the results of the katherine trial in her2 breast cancer
-
1:42
dr. hamilton on the her2climb trial in metastatic her2 breast cancer